CPT 81313 PCA3/KLK3 Reimbursement & Benchmarks

CPT code 81313 designates a molecular diagnostic assay that quantifies the ratio of PCA3 to KLK3 gene expression, a marker used in the evaluation of prostate disease. As a specialized molecular laboratory service, this test supports clinical decision-making in urology and oncology by providing biomarker data that can inform risk assessment and further diagnostic workups. Nationally, growth in precision diagnostics and molecular testing utilization makes such codes increasingly relevant to laboratory reimbursement and coverage policies.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns and typical sites of service for molecular assays, benchmark considerations for laboratory billing, and clinical context describing when a PCA3/KLK3 ratio assay is used. The publication also outlines common billing components and coding considerations for labs submitting claims for molecular diagnostic services.

This summary provides a concise resource for clinicians, laboratory billing staff, and policy analysts seeking to understand the clinical role and payer landscape for CPT code 81313. Detailed benchmarks, policy updates, and payer-specific coverage language are presented in the main publication.

Billing Code Overview

CPT code 81313 describes a laboratory test that measures the ratio between two genes: nonprotein coding prostate cancer antigen 3 (PCA3) and prostate specific antigen kallikrein related peptidase 3 (KLK3). This assay is used to evaluate gene expression relevant to prostate disease and is performed by a clinical laboratory analyst.

Service type: Molecular diagnostic laboratory test (gene expression ratio assay)
Typical site of service: Clinical laboratory or reference lab (blood or urine specimen processing and molecular analysis)

Data not available in the input.

Clinical Context

A 62-year-old man with a prior elevated prostate-specific antigen (PSA) and a recent negative or indeterminate prostate biopsy is referred for molecular testing to refine prostate cancer risk. The clinician collects a urine specimen after a digital rectal exam (DRE) and sends it to a CLIA-certified laboratory. The laboratory performs the quantitative molecular assay to determine the ratio of nonprotein coding PCA3 (prostate cancer antigen 3) RNA to KLK3 (prostate-specific antigen, kallikrein related peptidase 3) RNA, producing a PCA3 score used by the treating urologist to help decide on repeat biopsy or active surveillance.

The typical workflow: the outpatient urology clinic orders testing, documents indication (e.g., elevated PSA, abnormal DRE, prior negative biopsy), obtains informed consent and collects post-DRE urine per the test kit instructions, and ships the specimen to the reference lab. The reference laboratory logs the specimen, performs nucleic acid extraction and quantitative analysis, calculates the PCA3:KLK3 ratio, reports the result to the ordering clinician, and bills using 81313 for the technical laboratory test.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation component if applicable (rare for fully automated molecular assays).

Taxonomy Code	Specialty	Notes
208800000X	Urology	Urologists commonly order PCA3 testing for prostate cancer risk assessment.
207RH0000X	Hematology & Oncology	Medical oncologists may use results when evaluating prostate cancer management.
261QM2500X	Molecular Pathology	Laboratory molecular pathologists oversee test performance and interpretation.
208D00000X	Diagnostic Radiology	Radiologists are less commonly directly involved but may correlate imaging findings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R97.2`	Elevated prostate specific antigen [PSA]	Common indication for ordering PCA3 to help decide on repeat biopsy or further workup.
`N40.0`	Enlarged prostate with urinary obstruction	Benign prostatic enlargement can raise PSA and prompt adjunctive PCA3 testing to evaluate cancer risk.
`R31.9`	Hematuria, unspecified	Hematuria may trigger urologic evaluation where PCA3 is considered as part of prostate cancer assessment.
`Z85.46`	Personal history of malignant neoplasm of prostate	Used when monitoring men with prior prostate cancer; PCA3 may be used in surveillance contexts.
`Z12.5`	Encounter for screening for malignant neoplasm of prostate	PCA3 may be used in the context of enhanced screening strategies in select patients.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`84153`	Prostate specific antigen (PSA); total	Baseline serum PSA measurement used before or alongside PCA3 testing.
`84152`	Prostate specific antigen (PSA); free	Free PSA fraction may be used with PCA3 to refine risk assessment.
`88305`	Level IV surgical pathology, gross and microscopic examination	Pathology code for prostate biopsy tissue evaluation when biopsy is performed following elevated PCA3.
`55700`	Biopsy, prostate; needle or punch, single or multiple, any approach	Procedure code for transrectal or transperineal prostate biopsy performed after risk stratification including PCA3.
`81292`	Prostate cancer, somatic mutation testing, targeted sequence analysis (example)	Additional molecular testing that may be ordered on biopsy tissue for therapeutic decision-making.

OpenPayer

Summary & Overview

CPT 81313: PCA3/KLK3 Gene Expression Ratio Assay